



# External eye disease

Francesca Harman  
September 2019



# Dry Eye


## Tear Film



# DEWS II


“Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles.”



- Poor quantity – aqueous deficient
- Poor quality - evaporative
- ..... inflammation



# Symptoms



- Irritation, burning, stinging, light sensitivity, foreign body sensation
- *Fluctuating vision*







# Diagnosis

- OSDI questionnaire
- Lid margin disease
- Tear break up time
- Conjunctival / corneal punctate staining
- Schirmers test
- Osmolarity
- MMP
- Lipiview



# Blepharitis

- Common, chronic, bilateral
- Staphylococcal or seborrhoeic
- Sx: burning, grittiness, dry eye
- Ex: crusting, lid notching and telangiectasia, hyperaemia



# Symptomatic Therapy

1. Modify environment
2. Lid hygiene / hot compresses
3. Avoid medication with anti-cholinergic s/e
4. Avoid multiple preserved eye drops
5. Punctal occlusion
6. Minimize corneal exposure (tarsorrhaphy, GPCL)
7. Lubricants
8. Biologic tear substitutes - serum
9. Lipiflow



# Lubricants

- Main variables are electrolytes (K, HCO<sub>3</sub>), osmolarity, viscosity, preservatives
- Polymers determine viscosity, retention time, adhesion to surface
- Absence of preservatives more important than type polymer
  - BAK toxic to epithelium
- *Temporarily* improve subj and obj parameters
- No evidence any one agent is superior except hyaluronate if epithelial defect

# NW London formulary

- Hypromellose - first line
- polyvinyl alcohol - liquifilm, sno tears
- yellow soft paraffin - simple eye ointment
- liquid paraffin - lacilube, xailin
- carmellose - optive
- hydroxymethylcellulose - minims
- carbomer 980 - viscotears
- sodium hyaluronate 0.1%, 0.2% - hylotears, optive fusion, hyloforte

# Causative therapy

- Cyclosporin A
- Corticosteroids
- Tetracyclines
- Omega 3

# Public Health England advice

- ‘prescription for treatment of dry or sore eyes should not routinely be offered in primary care as the condition is appropriate for self-care’
- ‘most cases of sore tired eyes resolve themselves
- Refer to us if not!




# CATARACTS

what to refer and what happens then

# Cataract: clouding of the natural lens

- blurring or dim vision
- glare - especially night
- haloes round lights
- double or ghost images





PPwT form – Cataract Surgery

This form is for clinicians to complete where North West London patients meet NWL CCGs PPwT policy. Any queries relating to this form will be responded to within 5 working days.

TO VALIDATE THIS REFERRAL, email it to: [nwlccgs.ppwtfir@nhs.net](mailto:nwlccgs.ppwtfir@nhs.net) only using your [nhs.net](mailto:nhs.net) email account.

PATIENT CONSENT (Applicant is requested to record patients consent within their individual health records)

I confirm that this Planned procedure with Threshold (PPwT) Form has been discussed in full with the patient.  
I confirm that all the access criteria have been met and this patient is therefore eligible for NHS funded treatment.

The patient is aware that they are consenting for the PPWT Team to access confidential clinical and patient identifiable information held by clinical staff involved in their care about them as a patient to enable full consideration of this funding request.

On an annual basis, the PPWT team will conduct audits on a sample of records to ensure that the thresholds required by the PPwT Policy have been met. The audits also help to ensure that the quality of our record keeping adheres to the standards outlined by the General Medical Council and/or the Nursing and Midwifery Council (or other relevant body).

The patient identifiable information will not be shared with any other organisation and to ensure confidentiality, the patient's details will be redacted if it needs to be reviewed by the clinical Triage.

YES  NO  [Please indicate]

Date:

Designation (Please mark one): Trust Clinician <input type="checkbox"/>		GP <input type="checkbox"/>	Other, please specify
Name of Responsible Clinician	GP Practice code		
Name of Trust/GP Practice and Address/Telephone	CCG Name		
Chosen Provider	GMC/HPC code		
NHS/PAS No:	Date of Decision to Treat:		

For GP Use

Patient Name	D.O.B:		(dd/mm/yyyy)
Patient Address			
Patient Phone number			
Gender	Ethnicity		
Preferred service provider	Alternative provider		
Has the patient previously visited this hospital? If yes please specify hospital number			
Interpreter required? If yes please specify the language			
Is transport required?	Yes <input type="checkbox"/>	No <input type="checkbox"/>	
Is patient housebound?	Yes <input type="checkbox"/>	No <input type="checkbox"/>	
Safeguarding issues	Yes <input type="checkbox"/>	No <input type="checkbox"/>	Carer Information



THRESHOLDS FOR TREATMENT: Either threshold 1 or 2 must be met

1)  
a. Patient has a best corrected visual acuity of 6/9 (LogMAR 0.18) or worse in :  
 RIGHT EYE YES  NO   
 LEFT EYE YES  NO   
 BOTH EYES YES  NO

AND

b. Has impairment in lifestyle such as significant effect on activities of daily living, leisure activities, and risk of falls. YES  NO

2)

a. Surgery is indicated for management of ocular comorbidities e.g. management of glaucoma, obscuring view of retina in retinal screening YES  NO

Or

b. Significant optical imbalance (anisometropia or aniseikonia) following cataract surgery on the first eye YES  NO

Supporting Information - Please provide supporting evidence as this form is subject to clinical triage.

END OF FORM

VA 6/9 or worse and lifestyle impaired

Prescription details from current

	Vision	Sph	Cyl	Axis	Prism H	Prism V	VA	Add	Near VA	Previous VA
RE	6/20	+1.75	-1.75	90			6/7.5	+2.50	N8	6/7.5 +2 13 March 2018
LE	6/10	+0.75	-1.25	95			6/6	+2.50	N5	6/6


RE Intra-Ocular Pressure mmHg	
LE Intra-Ocular Pressure mmHg	

RE Disc Appearance	6, WEST 0069	Visual Fields
LE Disc Appearance	1 slight test	

Reason for Referral: Cataract / ~~Acute cataract~~

- Px presented complaining reduced vision in the RE
- On Ophthalmoscopy I found nuclear cataracts in both eyes (R>L)
- Please see Mr French for cataract extraction

Yours Sincerely,



Nund Vyas

GOC/GMC No.: 01-26466

Statement: The reason for this referral has been explained to the patient or guardian who agrees to it. The patient or guardian also consents to information being exchanged between the Hospital Eye Service, their General Medical Practitioner and optometrist or ophthalmic medical practitioner.

02664280

19.6

THE HILLINGDON HOSPITAL NHS FOUNDATION TRUST

COMMUNITY OPHTHALMOLOGY SERVICE  
REFERRAL FORM

<b>GP Name and Address</b> BOOTS OPTICIANS 49 STATION ROAD HAYES MIDDLESEX UB3 4BE	<b>Optometrists name and address</b> Glenale MC RECEIVED 19 JUN 2019 UB3 5DA
<b>Phone/Fax</b> Tel : 0208 848 0337 Fax : 0208 573 4336	<b>Phone/Fax</b> WORKING CENTRE 02088978288
<b>nhs.net e-mail:</b>	<b>nhs.net e-mail:</b>

<b>Patient's Surname, Forename and Address including postcode</b>			
<b>NHS Number</b>		<b>Date of Referral</b>	07-07-50
<b>Telephone No</b>	07932163599	<b>Date of Referral</b>	19-6-19

**Main Symptoms / condition requiring referral and any relevant information:**

pc clo wgs vision in left eye  
lens opacity in both eyes L > R  
Both eyes px  
Please refer for an ophthal opinion

**General Report, including medical history, medication, allergies etc.**

pc is Diabetic

11.48


<b>Tel (Routine): 01895279200</b>	<b>Tel (Urgent):</b>
<b>Fax (Routine): 01895279902</b>	<b>Fax (Urgent): 01895279247</b>
<b>Email: thh-tr.cos@nhs.net</b>	

# Aetiology

- age related
- trauma - blunt or perforating
- systemic - DM
- iatrogenic - steroids
- congenital



# Aetiology

- age related
- trauma - blunt or perforating
- systemic - DM
- iatrogenic - steroids
- congenital






# Aetiology

- age related
- trauma - blunt or perforating
- systemic - DM
- iatrogenic - steroids
- congenital



# Aetiology

- age related
- trauma - blunt or perforating
- systemic - DM
- iatrogenic - steroids
- congenital



# Pre-op

- Can they lie still?
- Will they bleed?

# Pre-op

- Can they lie still?
- Will they bleed?
- Biometry - axial length + corneal curvature

Name: \_\_\_\_\_  
 Date of Birth: \_\_\_\_\_  
 Exam Date: \_\_\_\_\_

n: 1.3375



**Preoperative Data:**

AL: 22.84 mm (SD = 0.01 mm, SNR = 883.4)  
 K1: 43.21 D / 7.81 mm @ 169°  
 K2: 43.60 D / 7.74 mm @ 79°  
 SE: 43.41 D  
 Cyl.: 0.39 D @ 79°  
 R: 7.78 mm (SD = 0.00 mm)

Target Ref.: plano  
 opt. ACD: 2.94 mm

Visual Acuity:  
 Refraction:  
 Eye Status: phakic

OD

right

SN 60 WF		MA 50		LI61se		AC MTA	
A Const:	118.7	A Const:	118.9	A Const:	118.5	A Const:	115.8
IOL (D)	REF (D)	IOL (D)	REF (D)	IOL (D)	REF (D)	IOL (D)	REF (D)
24.5	-1.00	25.0	-1.16	24.5	-1.21	21.0	-1.12
24.0	-0.64	24.5	-0.80	24.0	-0.84	20.5	-0.71
23.5	-0.28	24.0	-0.44	23.5	-0.48	20.0	-0.30
<b>23.0</b>	<b>0.07</b>	<b>23.5</b>	<b>-0.09</b>	<b>23.0</b>	<b>-0.12</b>	<b>19.5</b>	<b>0.11</b>
22.5	0.42	23.0	0.26	22.5	0.24	19.0	0.51
22.0	0.77	22.5	0.60	22.0	0.59	18.5	0.90
21.5	1.11	22.0	0.94	21.5	0.93	18.0	1.29

**Preoperative Data:**

AL: 22.94 mm (SD = 0.01 mm, SNR = 150.9)  
 K1: 42.72 D / 7.90 mm @ 26°  
 K2: 43.60 D / 7.74 mm @ 116°  
 SE: 43.16 D  
 Cyl.: 0.88 D @ 116°  
 R: 7.82 mm (SD = 0.00 mm)

Target Ref.: plano  
 opt. ACD: 3.43 mm

Visual Acuity:  
 Refraction:  
 Eye Status: phakic

OS

left

SN 60 WF		MA 50		LI61se		AC MTA	
A Const:	118.7	A Const:	118.9	A Const:	118.5	A Const:	115.8
IOL (D)	REF (D)	IOL (D)	REF (D)	IOL (D)	REF (D)	IOL (D)	REF (D)
24.5	-1.05	25.0	-1.21	24.5	-1.26	21.0	-1.15
24.0	-0.69	24.5	-0.85	24.0	-0.89	20.5	-0.74
23.5	-0.33	24.0	-0.49	23.5	-0.52	20.0	-0.33
<b>23.0</b>	<b>0.03</b>	<b>23.5</b>	<b>-0.14</b>	<b>23.0</b>	<b>-0.16</b>	<b>19.5</b>	<b>0.08</b>
22.5	0.38	23.0	0.21	22.5	0.19	19.0	0.48
22.0	0.72	22.5	0.56	22.0	0.55	18.5	0.87
21.5	1.07	22.0	0.90	21.5	0.89	18.0	1.27

(\* = Changed manually, ! = Borderline Value)

# Intraocular lenses

- monofocal
- (monovision)
- multifocal / trifocal
- extended depth of focus
- toric





# Intraocular lenses

- monofocal
- (monovision)
- multifocal / trifocal
- extended depth of focus
- toric



# Intraocular lenses

- monofocal
- (monovision)
- multifocal / trifocal
- extended depth of focus
- toric



# Complications

Intraoperative:

posterior capsule rupture (1.1

corneal damage

iris damage (tamsulosin)

anaesthetic issue



# Complications

Postoperative:

endophthalmitis


ocular surface irritation



persistant uveitis / CMO

floaters / RD

dysphotopsia

posterior capsule opacification





# Useful abbreviations

- BSCVA best spectacle corrected visual acuity
- PH pinhole, UA unaided
- AC anterior chamber
- IOL intraocular lens
- IOP intraocular pressure
- PCO posterior capsule opacification
- YAG laser (Nd:YAG neodymium-doped yttrium aluminium garnet)
- PCR posterior capsule rupture
- CMO cystoid macular oedema
- RDW retinal detachment warning

*Thank you*